Home Alzheimer’s Disease Maintenance With Atezolizumab Combo Is Favorable Compared With Placebo/Chemotherapy in ES-SCLC

Maintenance With Atezolizumab Combo Is Favorable Compared With Placebo/Chemotherapy in ES-SCLC

Updated data regarding overall survival (OS) from the IMpower133 trial (NCT02763579) indicate that maintenance therapy with atezolizumab (Tecentriq) plus carboplatin and etoposide (CP/ET) is superior to placebo and CP/ET for the treatment of extensive-stage small cell lung cancer (ES-SCLC).1

Lead study author Martin Reck, MD, PhD, head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf in Germany, presented OS and progression-free survival (PFS) results from the phase 3 trial at the 2020 World Conference on Lung Cancer Singapore.

Investigators found that median OS was longer in the atezolizumab + CP/ET (n = 154) compared with the placebo + CP/ET arm (n = 164) among patients in the maintenance population. The median duration of follow-up was 13.9 months at the April 24, 2018 data cutoff.

The median OS was 15.7 versus 11.3 months in favor of the experimental arm (HR,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments